ThromboVision Completes Management Team With Finance Officer and Regulatory Affairs Director
HOUSTON, April 27, 2007 ----- ThromboVision, Inc., a Houston-based biomedical diagnostics company, has appointed Clarice Motter, CPA to be interim CFO/controller and LeAnn Latham to be director of regulatory affairs.
Motter will manage ThromboVision’s accounting, finance, treasury, tax and information technology functions as the company begins manufacturing and clinical trials. She served previously in the same capacity for MicroMed Technology.
Latham will develop the company’s regulatory strategies and compliance procedures and manage the FDA application process. Her experience in regulatory affairs, quality assurance, microbiology and sterilization will ensure the company’s products comply with US and international regulatory requirements.
“Clarice’s strategic financial background and LeAnn’s compliance expertise will help ThromboVision remain fiscally conservative and good stewards of our investors’ funds as we pursue clinical trails and subsequent FDA approval to market ThromboGuide (T-Guide®) risk assessment / risk modification platelet function solutions.” said Dr. Edward R. Teitel, president and CEO.
Biographical sketches follow.
Clarice Motter is a licensed CPA with more than 20 years experience as an accounting, financial, tax, and administrative professional. Her expertise includes establishing and managing all accounting, finance, treasury, budget, tax, credit, human resources, information technology, and administrative functions in both start-up and ongoing operations. She has worked with publicly held as well as privately owned companies and has experience in mergers and acquisitions, along with initial and follow-on public offerings.
Since 1990, Motter has served as interim CFO/controller for numerous private and public companies in construction, biotechnology, manufacturing, and service. Among her biotechnology clients were MicroMed Technology, Chrysalis Biotechnology, Zonagen and LifeCell Corporation. She began her career as a senior accountant with KPMG Peat Marwick, before moving into corporations as a controller.
Motter holds an MBA in accounting and information systems and a BA, both from the University of California at Los Angeles (UCLA).
Prior to joining ThromboVision, LeAnn Latham was director of regulatory affairs and quality assurance for NovoSci, where she developed regulatory strategies for new product introduction. Before joining NovoSci, Latham was the quality assurance manager for Houston Biotechnology, where she provided manufacturing and regulatory support for an investigational new drug in phase II clinical trails. Latham started her career as a microbiology supervisor for Seamless Hospital Products, where she managed a microbiological quality assurance program for respiratory therapy device and drug manufacturing.
She holds a BS in medical technology, minor in chemistry, from Western Carolina University and is certified by the American Society of Clinical Pathologists.
ThromboVision, Inc. is a biomedical company committed to enabling people to lead longer and healthier lives. ThromboVision provides easy-to-use, rapid-response, cost-effective, and versatile point-of-care clinical diagnostic discoveries that advance medical diagnosis. The company’s products will improve medical care by assisting physicians in diagnosing and managing critical cardiovascular risk factors, especially those related to platelet function and antiplatelet drug therapy. www.thrombovision.com
ThromboVision is a Houston Technology Center (HTC) client company. HTC is a business accelerator that assists Houston-based emerging technology companies in key sectors such as Energy, Information Technology, Life Sciences, Nanotechnology and NASA-originated technologies. www.houstontech.org
SAFE HARBOR STATEMENT
This release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Statements in this release regarding ThromboVision’s business that are not historical facts are “forward-looking statements,” which involve risks and uncertainties that could cause actual results to differ materially from any future results, performance, or achievements expressed or implied by such statements.
CONTACT: Edward R. Teitel, MD - 713.491.4449 (office)
Sally I Evans, APR - 713.660.7990 (office) or 713.557.2461 (cell)
8036 El Rio
Houston, TX 77054